Clinical trial information
Select trial for more information
- Overview
- Clinical Trials
- Abbreviations
Target Overview
Programmed cell death-1 (PD-1) is a cell surface receptor that interacts with 2 ligands, programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2), to deliver inhibitory signals to T cells, limiting their function.1
Cytotoxic T–lymphocyte-associated protein 4 (CTLA-4) is expressed exclusively on the surface of effector T cells (Teff) and regulatory T cells (Tregs).1 CTLA-4 serves to inhibit T-cell activation through ligand competition with the costimulatory receptor, CD28.1
PD-1 and CTLA-4 blockade has been shown to potentiate anti-tumor immunity across a number of tumor types.2
Compound Overview
Volrustomig (formerly MEDI5752) is an innovative, investigational, bispecific dual checkpoint inhibitor targeting both CTLA-4 and PD-1. It is designed to deliver coordinated and targeted blockade of PD-1 and CTLA-4 on the same T cell, potentially enhancing immune activation compared to co-administration.3
Volrustomig’s bispecific modality enables:
- Preferential binding to CTLA‑4 on PD-1-positive T cells, enhancing productive T cell activity3
- Dose-dependent increase in T cell proliferation that exceeds that of PD-L1 + CTLA-4 inhibitor co-administration4
- Antitumor immune response that surpasses the outcomes that are achievable with current immunotherapy combinations4,5
Volrustomig is currently being clinically evaluated in the treatment of advanced solid tumors, including Mesothelioma, mNSCLC, HNSCC, Cervical cancer, Gastric/GEJ cancer, advanced solid tumors, BTCs, HCC, mCRC, RCC
Mechanism of Action
References
1. Pardoll DM. Nat Rev Cancer. 2012;12(4):252-264. 2. Roy D, Gilmour C, Patnaik S, Wang LL. Front Immunol. 2023;14:1264327. 3. Dovedi SJ, Elder MJ, Yang C, et al. Cancer Discov. 2021;11(5):1100-1117. 4. Tran B, Viskoboynik M, Kim S-W, Lemech C. Cancer Res. 2022;82(suppl 12):CT016-CT016. 5. Achour I, Kuziora M, Song F, et al. Presented at: American Association for Cancer Research (AACR) Meeting; April 5–10, 2024; San Diego, CA. Poster 3627)
Arrange By
Selected Filter(s)
Abbreviations
1L
first line
ADA
anti-drug antibody
AJCC
American Joint Committee on Cancer
ALK
anaplastic lymphoma kinase
BICR
blinded independent central review
cCRT
concurrent chemoradiation therapy
CD28
cluster of differentiation 28
CD80
cluster of differentiation 80
CD86
cluster of differentiation 86
CNS
central nervous system
COPD
chronic obstructive pulmonary disease
CRC
colorectal cancer
CT
chemotherapy
CT
computed tomography
CTLA-4
cytotoxic T–lymphocyte-associated antigen 4
DoR
duration of response
ECOG
Eastern Cooperative Oncology Group
ECOG PS
Eastern Cooperative Oncology Group Performance Score
EGFR
epidermal growth factor receptor
FOLFIRI
irinotecan, 5-FU, leucovorin
FOLFOX
folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin
GHS
global health status
HER2
human epidermal growth factor receptor 2
HIV
human immunodeficiency virus
HNSCC
head and neck squamous cell carcinoma
IASLC
International Association For The Study Of Lung Cancer
IV
intravenous
mAb
monoclonal antibody
mCRC
metastatic CRC
MHC
major histocompatibility complex
mNSCLC
metastatic NSCLC
mRECIST
modified Response Evaluation Criteria in Solid Tumors
MRI
magnetic resonance imaging
MSS
microsatellite-stable
NSCLC
non-small cell lung cancer
ORR
overall or objective response rate
OS
overall survival
PD-1
programmed cell death-1
PD-L1
programmed cell death ligand-1
PD-L2
programmed cell death ligand-2
PDC
platinum doublet chemotherapy
PFS
progression-free survival
PFS2
time to second progression or death
PK
pharmacokinetics
pMMR
mismatch repair proficient
PS
phosphatidylserine
PtCh
platinum-based chemotherapy
Q*W
every * weeks
QoL
quality of life
R
randomization
RCC
renal cell carcinoma
RECIST v1.1
Response Evaluation Criteria in Solid Tumors version 1.1
ROS1
ROS proto-oncogene 1
RT
radiotherapy
SCLC
small cell lung cancer
SoC
standard of care
TCR
T-cell receptor
Teff
effector T cells
TNM
tumor node metastasis staging
Treg
regulatory T cell
TROP2
trophoblast cell-surface antigen 2
WHO
World Health Organization
XELOX
capecitabine, oxaliplatin
Target Overview
Programmed cell death-1 (PD-1) is a cell surface receptor that interacts with 2 ligands, programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2), to deliver inhibitory signals to T cells, limiting their function.1
Cytotoxic T–lymphocyte-associated protein 4 (CTLA-4) is expressed exclusively on the surface of effector T cells (Teff) and regulatory T cells (Tregs).1 CTLA-4 serves to inhibit T-cell activation through ligand competition with the costimulatory receptor, CD28.1
PD-1 and CTLA-4 blockade has been shown to potentiate anti-tumor immunity across a number of tumor types.2
Compound Overview
Volrustomig (formerly MEDI5752) is an innovative, investigational, bispecific dual checkpoint inhibitor targeting both CTLA-4 and PD-1. It is designed to deliver coordinated and targeted blockade of PD-1 and CTLA-4 on the same T cell, potentially enhancing immune activation compared to co-administration.3
Volrustomig’s bispecific modality enables:
- Preferential binding to CTLA‑4 on PD-1-positive T cells, enhancing productive T cell activity3
- Dose-dependent increase in T cell proliferation that exceeds that of PD-L1 + CTLA-4 inhibitor co-administration4
- Antitumor immune response that surpasses the outcomes that are achievable with current immunotherapy combinations4,5
Volrustomig is currently being clinically evaluated in the treatment of advanced solid tumors, including Mesothelioma, mNSCLC, HNSCC, Cervical cancer, Gastric/GEJ cancer, advanced solid tumors, BTCs, HCC, mCRC, RCC
Mechanism of Action
References
1. Pardoll DM. Nat Rev Cancer. 2012;12(4):252-264. 2. Roy D, Gilmour C, Patnaik S, Wang LL. Front Immunol. 2023;14:1264327. 3. Dovedi SJ, Elder MJ, Yang C, et al. Cancer Discov. 2021;11(5):1100-1117. 4. Tran B, Viskoboynik M, Kim S-W, Lemech C. Cancer Res. 2022;82(suppl 12):CT016-CT016. 5. Achour I, Kuziora M, Song F, et al. Presented at: American Association for Cancer Research (AACR) Meeting; April 5–10, 2024; San Diego, CA. Poster 3627)
Clinical trial information
Select trial for more information
Arrange By
Selected Filter(s)
Abbreviations
1L
first line
ADA
anti-drug antibody
AJCC
American Joint Committee on Cancer
ALK
anaplastic lymphoma kinase
BICR
blinded independent central review
cCRT
concurrent chemoradiation therapy
CD28
cluster of differentiation 28
CD80
cluster of differentiation 80
CD86
cluster of differentiation 86
CNS
central nervous system
COPD
chronic obstructive pulmonary disease
CRC
colorectal cancer
CT
chemotherapy
CT
computed tomography
CTLA-4
cytotoxic T–lymphocyte-associated antigen 4
DoR
duration of response
ECOG
Eastern Cooperative Oncology Group
ECOG PS
Eastern Cooperative Oncology Group Performance Score
EGFR
epidermal growth factor receptor
FOLFIRI
irinotecan, 5-FU, leucovorin
FOLFOX
folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin
GHS
global health status
HER2
human epidermal growth factor receptor 2
HIV
human immunodeficiency virus
HNSCC
head and neck squamous cell carcinoma
IASLC
International Association For The Study Of Lung Cancer
IV
intravenous
mAb
monoclonal antibody
mCRC
metastatic CRC
MHC
major histocompatibility complex
mNSCLC
metastatic NSCLC
mRECIST
modified Response Evaluation Criteria in Solid Tumors
MRI
magnetic resonance imaging
MSS
microsatellite-stable
NSCLC
non-small cell lung cancer
ORR
overall or objective response rate
OS
overall survival
PD-1
programmed cell death-1
PD-L1
programmed cell death ligand-1
PD-L2
programmed cell death ligand-2
PDC
platinum doublet chemotherapy
PFS
progression-free survival
PFS2
time to second progression or death
PK
pharmacokinetics
pMMR
mismatch repair proficient
PS
phosphatidylserine
PtCh
platinum-based chemotherapy
Q*W
every * weeks
QoL
quality of life
R
randomization
RCC
renal cell carcinoma
RECIST v1.1
Response Evaluation Criteria in Solid Tumors version 1.1
ROS1
ROS proto-oncogene 1
RT
radiotherapy
SCLC
small cell lung cancer
SoC
standard of care
TCR
T-cell receptor
Teff
effector T cells
TNM
tumor node metastasis staging
Treg
regulatory T cell
TROP2
trophoblast cell-surface antigen 2
WHO
World Health Organization
XELOX
capecitabine, oxaliplatin